Meeting Coverage

ASBMR

American Society for Bone and Mineral Research

One-Two Punch of Romosozumab, Denosumab Improved BMD and Reduced Fractures

Taking the bone-forming agent followed by the antiresorptive was better than denosumab alone

ASBMR over a photo of the Austin Convention Center in Austin, Texas

Latest ASBMR Meetings

Novel Agent Hints at Bone Growth Boost Without Hematopoietic Risks

Phase I study shows ability to modulate cell signaling

September 13, 2022
Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer

Areal BMD increased when given at the start of maximal estradiol depletion therapy

September 13, 2022
Fish Oil Supplement Fails to Reduce Hip Fractures

Further bad news for omega-3 fatty acids in VITAL trial analysis

September 12, 2022
Vitamin D Levels, Supplements Not Linked to COVID Infection Risk

High or low levels made no difference among healthy people

September 12, 2022
Cardiovascular Risks Not Increased With Denosumab

Large observational databases mitigate concerns about the osteoporosis therapy

September 12, 2022
Predicting Fractures in RA: Is FRAX Useful in the Modern Treatment Era?

Algorithm held its own, but not many study patients were on biologics

September 11, 2022
Good News, Bad News for Global Hip Fracture Rates

Incidence has declined, but burden will increase as older population grows

September 10, 2022
Forteo Injection May Soon Face Competition From a Pill

Same peptide formulated for oral administration passes phase II test

October 7, 2021
Is This the Future of Corticosteroids?

Novel agent, aimed at doing away with adverse metabolic effects, proves mettle in DMD

October 5, 2021
New Parathyroid Hormone Disease Guidelines Make Their Debut

Updates reflect evidence accumulated in recent years, though research needs remain

October 4, 2021
Supplements to Prevent Bone Breaks? VITAL Says Forget It

Landmark trial throws more cold water on vitamin D, omega-3 pills

October 3, 2021
Bone Disease Drug Misses Endpoint, But Still Very Much Alive

Favorable results on most outcomes may suggest poor choice of primary

October 2, 2021
No Rise in Fracture Risk With SGLT2 Inhibition

Weight change in type 2 diabetes on these drugs did not increase risk of osteoporotic fractures

September 15, 2020
Modest Increase in AFib Risk With Osteoporosis Drug

Absolute risk was low for patients receiving zoledronic acid versus denosumab

September 14, 2020